|27.17 0.58 (2.18%)||12-08 16:00|
|Targets||6-month :||32.76||1-year :||38.26|
|Resists||First :||28.04||Second :||32.76|
|Supports||First :||22.7||Second :||19.39|
|MAs||MA(5) :||25.9||MA(20) :||23.82|
|MA(100) :||37.05||MA(250) :||41.15|
|MACD||MACD :||0.7||Signal :||0.1|
|%K %D||K(14,3) :||90.5||D(3) :||90.7|
|52-week||High :||63.08||Low :||19.34|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MORF ] has closed above the upper band by 6.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 55.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||28.07 - 28.15||28.15 - 28.24|
|Low:||26.26 - 26.35||26.35 - 26.46|
|Close:||26.99 - 27.14||27.14 - 27.31|
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||50 (M)|
|Held by Insiders||3.867e+007 (%)|
|Held by Institutions||16.6 (%)|
|Shares Short||5,430 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-2 %|
|Return on Assets (ttm)||341.2 %|
|Return on Equity (ttm)||-17.3 %|
|Qtrly Rev. Growth||6.66e+006 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||-18.49|
|Qtrly Earnings Growth||-3.3 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-109 (M)|
|Price to Book value||0|
|Price to Sales||-1.48|
|Price to Cash Flow||2.52|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|